Skip to main content

Vivani Medical, Inc.

VANI
Exchange
Nasdaq
Industry
Electromedical & Electrotherapeutic Apparatus
SEC CIK
0001266806

In the last 90 days, Vivani Medical, Inc. insiders filed 2 open-market purchases and 0 sales; 38 institutions reported holding it in 13F filings for Q2 2026, worth $6.47M in total; no superinvestor holds it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 13, 2026, 1:18 AM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Vivani Medical, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021!
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 26, 2026Mar 13, 2025Mar 26, 2024––
Revenue$0$0–$475.0K$12.0K
Cost of revenue––––$130.0K
Gross profit––––$130.0K
Operating expenses$27.6M$24.7M$27.0M$21.2M$9.06M
Research and development$18.1M$15.7M$17.0M$14.2M$2.37M
Selling, general and administrative$9.43M$8.93M$10.0M$7.07M$6.32M
Operating income-$27.6M-$24.7M-$27.0M-$21.2M-$8.93M
Net income-$26.6M-$23.5M-$25.7M-$13.9M-$8.92M
EPS, basic$-0.43$-0.43–––
EPS, diluted$-0.43$-0.43–––
Weighted shares, basic62.4M55.0K–––
Weighted shares, diluted62.4M55.0K–––
Margins and growth
Gross margin––––1083.3%
Operating margin–––-4471.8%-74441.7%
Net margin–––-2924.0%-74341.7%
Revenue growth, year over year–––+3,858.3%−25.0%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Vivani Medical, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 26, 2026Mar 13, 2025Mar 26, 2024––
Cash and equivalents$16.2M$18.4M$20.7M–$69.6M
Total current assets$17.9M$20.4M$23.1M$47.5M$70.5M
Property, plant and equipment$2.88M$1.69M$1.73M$1.18M$117.0K
Total assets$39.4M$41.6M$45.8M$51.1M$70.9M
Accounts payable$1.03M$817.0K$542.0K$1.18M$519.0K
Total current liabilities$6.60M$5.99M$5.72M$6.82M$2.46M
Total liabilities$23.7M$24.0M$25.0M$6.82M$2.51M
Shareholders' equity$15.7M$17.6M$20.8M$44.3M$68.4M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Vivani Medical, Inc., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedMar 26, 2026Mar 13, 2025Mar 26, 2024––
Operating cash flow-$24.3M-$20.8M-$23.7M-$18.8M-$9.19M
Capital expenditures$1.17M$556.0K$887.0K$338.0K$14.0K
Free cash flow-$25.5M-$21.3M-$24.6M-$19.1M-$9.20M
Depreciation and amortization$424.0K$400.0K$357.0K$381.0K$70.0K
Stock-based compensation$1.48M$1.61M$1.86M$1.30M$75.0K
Investing cash flow-$1.17M-$556.0K-$887.0K-$338.0K-$14.0K
Financing cash flow$23.3M$19.1M$133.0K$63.4M$75.6M
Net change in cash-$2.12M-$2.30M-$24.4M$44.3M$66.4M
Ratio
Stock-based compensation, % of revenue–––272.8%625.0%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Vivani Medical, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Nov 12, 202690.2M+23.6%SEC
Aug 13, 202690.2M+52.3%SEC
May 12, 202686.2M+45.6%SEC
Mar 25, 202684.6M+42.9%SEC
Nov 12, 202573.0M+23.2%SEC
Aug 12, 202559.2M+7.2%SEC
May 12, 202559.2M+7.8%SEC
Mar 28, 202559.2M+7.8%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
  • A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.